ID   MUL1_HUMAN              Reviewed;         352 AA.
AC   Q969V5; B5M497; Q7Z431; Q9H9B5;
DT   20-FEB-2007, integrated into UniProtKB/Swiss-Prot.
DT   01-DEC-2001, sequence version 1.
DT   10-MAY-2017, entry version 141.
DE   RecName: Full=Mitochondrial ubiquitin ligase activator of NFKB 1;
DE            EC=2.3.2.27;
DE   AltName: Full=E3 SUMO-protein ligase MUL1;
DE   AltName: Full=E3 ubiquitin-protein ligase MUL1;
DE   AltName: Full=Growth inhibition and death E3 ligase;
DE   AltName: Full=Mitochondrial-anchored protein ligase;
DE            Short=MAPL;
DE   AltName: Full=Putative NF-kappa-B-activating protein 266;
DE   AltName: Full=RING finger protein 218;
DE   AltName: Full=RING-type E3 ubiquitin transferase NFKB 1 {ECO:0000305};
GN   Name=MUL1; Synonyms=C1orf166, GIDE, MAPL, MULAN, RNF218;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, SUBUNIT, INTERACTION WITH
RP   MAP3K7, SUBCELLULAR LOCATION, TISSUE SPECIFICITY, AND MUTAGENESIS OF
RP   HIS-319.
RX   PubMed=18591963; DOI=10.1038/cr.2008.75;
RA   Zhang B., Huang J., Li H.-L., Liu T., Wang Y.-Y., Waterman P.,
RA   Mao A.-P., Xu L.-G., Zhai Z., Liu D., Marrack P., Shu H.-B.;
RT   "GIDE is a mitochondrial E3 ubiquitin ligase that induces apoptosis
RT   and slows growth.";
RL   Cell Res. 18:900-910(2008).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Lung;
RX   PubMed=12761501; DOI=10.1038/sj.onc.1206406;
RA   Matsuda A., Suzuki Y., Honda G., Muramatsu S., Matsuzaki O.,
RA   Nagano Y., Doi T., Shimotohno K., Harada T., Nishida E., Hayashi H.,
RA   Sugano S.;
RT   "Large-scale identification and characterization of human genes that
RT   activate NF-kappaB and MAPK signaling pathways.";
RL   Oncogene 22:3307-3318(2003).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Teratocarcinoma;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Melanoma;
RX   PubMed=17974005; DOI=10.1186/1471-2164-8-399;
RA   Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U.,
RA   Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H.,
RA   Heubner D., Hoerlein A., Michel G., Wedler H., Koehrer K.,
RA   Ottenwaelder B., Poustka A., Wiemann S., Schupp I.;
RT   "The full-ORF clone resource of the German cDNA consortium.";
RL   BMC Genomics 8:399-399(2007).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16710414; DOI=10.1038/nature04727;
RA   Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D.,
RA   Dunham A., Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A.,
RA   Jones M.C., Gillson C., Searle S., Zhou Y., Kokocinski F.,
RA   McDonald L., Evans R., Phillips K., Atkinson A., Cooper R., Jones C.,
RA   Hall R.E., Andrews T.D., Lloyd C., Ainscough R., Almeida J.P.,
RA   Ambrose K.D., Anderson F., Andrew R.W., Ashwell R.I.S., Aubin K.,
RA   Babbage A.K., Bagguley C.L., Bailey J., Beasley H., Bethel G.,
RA   Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J., Buckley D.,
RA   Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y., Clarke G.,
RA   Clee C., Cobley V., Collier R.E., Corby N., Coville G.J., Davies J.,
RA   Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H.,
RA   Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L.,
RA   Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J.,
RA   Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R.,
RA   Hammond S., Harrison E.S.I., Hart E., Haugen E., Heath P.D.,
RA   Holmes S., Holt K., Howden P.J., Hunt A.R., Hunt S.E., Hunter G.,
RA   Isherwood J., James R., Johnson C., Johnson D., Joy A., Kay M.,
RA   Kershaw J.K., Kibukawa M., Kimberley A.M., King A., Knights A.J.,
RA   Lad H., Laird G., Lawlor S., Leongamornlert D.A., Lloyd D.M.,
RA   Loveland J., Lovell J., Lush M.J., Lyne R., Martin S.,
RA   Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W., McLaren S.,
RA   Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N.,
RA   Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V.,
RA   Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J.,
RA   Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E.,
RA   Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C.,
RA   Subramanian S., Sycamore N., Tracey A., Tromans A., Van Helmond Z.,
RA   Wall M., Wallis J.M., White S., Whitehead S.L., Wilkinson J.E.,
RA   Willey D.L., Williams H., Wilming L., Wray P.W., Wu Z., Coulson A.,
RA   Vaudin M., Sulston J.E., Durbin R.M., Hubbard T., Wooster R.,
RA   Dunham I., Carter N.P., McVean G., Ross M.T., Harrow J., Olson M.V.,
RA   Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence and biological annotation of human chromosome 1.";
RL   Nature 441:315-321(2006).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Brain, and Skin;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   FUNCTION, SUBCELLULAR LOCATION, AND TOPOLOGY.
RX   PubMed=18207745; DOI=10.1016/j.cub.2007.12.038;
RA   Neuspiel M., Schauss A.C., Braschi E., Zunino R., Rippstein P.,
RA   Rachubinski R.A., Andrade-Navarro M.A., McBride H.M.;
RT   "Cargo-selected transport from the mitochondria to peroxisomes is
RT   mediated by vesicular carriers.";
RL   Curr. Biol. 18:102-108(2008).
RN   [8]
RP   FUNCTION, SUBCELLULAR LOCATION, TISSUE SPECIFICITY, TOPOLOGY, AND
RP   MUTAGENESIS OF ARG-260; LYS-261 AND CYS-339.
RX   PubMed=18213395; DOI=10.1371/journal.pone.0001487;
RA   Li W., Bengtson M.H., Ulbrich A., Matsuda A., Reddy V.A., Orth A.,
RA   Chanda S.K., Batalov S., Joazeiro C.A.P.;
RT   "Genome-wide and functional annotation of human E3 ubiquitin ligases
RT   identifies MULAN, a mitochondrial E3 that regulates the organelle's
RT   dynamics and signaling.";
RL   PLoS ONE 3:E1487-E1487(2008).
RN   [9]
RP   FUNCTION AS SUMO LIGASE, AND INTERACTION WITH UBC9 AND DNM1L.
RX   PubMed=19407830; DOI=10.1038/embor.2009.86;
RA   Braschi E., Zunino R., McBride H.M.;
RT   "MAPL is a new mitochondrial SUMO E3 ligase that regulates
RT   mitochondrial fission.";
RL   EMBO Rep. 10:748-754(2009).
RN   [10]
RP   FUNCTION IN UBIQUITINATION OF AKT1.
RX   PubMed=22410793; DOI=10.1038/cr.2012.38;
RA   Bae S., Kim S.Y., Jung J.H., Yoon Y., Cha H.J., Lee H., Kim K.,
RA   Kim J., An I.S., Kim J., Um H.D., Park I.C., Lee S.J., Nam S.Y.,
RA   Jin Y.W., Lee J.H., An S.;
RT   "Akt is negatively regulated by the MULAN E3 ligase.";
RL   Cell Res. 22:873-885(2012).
RN   [11]
RP   FUNCTION, AND INTERACTION WITH MAVS.
RX   PubMed=23399697; DOI=10.1038/icb.2013.7;
RA   Jenkins K., Khoo J.J., Sadler A., Piganis R., Wang D., Borg N.A.,
RA   Hjerrild K., Gould J., Thomas B.J., Nagley P., Hertzog P.J.,
RA   Mansell A.;
RT   "Mitochondrially localised MUL1 is a novel modulator of antiviral
RT   signaling.";
RL   Immunol. Cell Biol. 91:321-330(2013).
RN   [12]
RP   UBIQUITINATION AT LYS-52; LYS-273 AND LYS-299.
RX   PubMed=25621951; DOI=10.1038/ncb3097;
RA   Cunningham C.N., Baughman J.M., Phu L., Tea J.S., Yu C., Coons M.,
RA   Kirkpatrick D.S., Bingol B., Corn J.E.;
RT   "USP30 and parkin homeostatically regulate atypical ubiquitin chains
RT   on mitochondria.";
RL   Nat. Cell Biol. 17:160-169(2015).
CC   -!- FUNCTION: Exhibits weak E3 ubiquitin-protein ligase activity. E3
CC       ubiquitin ligases accept ubiquitin from an E2 ubiquitin-
CC       conjugating enzyme in the form of a thioester and then directly
CC       transfer the ubiquitin to targeted substrates. Can ubiquitinate
CC       AKT1 preferentially at 'Lys-284' involving 'Lys-48'-linked
CC       polyubiquitination and seems to be involved in regulation of Akt
CC       signaling by targeting phosphorylated Akt to proteosomal
CC       degradation. Proposed to preferentially act as a SUMO E3 ligase at
CC       physiological concentrations. Plays a role in the control of
CC       mitochondrial morphology. Promotes mitochondrial fragmentation and
CC       influences mitochondrial localization. The function may implicate
CC       its ability to sumoylate DNM1L. Inhibits cell growth. When
CC       overexpressed, activates JNK through MAP3K7/TAK1 and induces
CC       caspase-dependent apoptosis. Involved in the modulation of innate
CC       immune defense against viruses by inhibiting DDX58-dependent
CC       antiviral response. Can mediate DDX58 sumoylation and disrupt its
CC       polyubiquitination. {ECO:0000269|PubMed:18207745,
CC       ECO:0000269|PubMed:18213395, ECO:0000269|PubMed:18591963,
CC       ECO:0000269|PubMed:19407830, ECO:0000269|PubMed:22410793,
CC       ECO:0000269|PubMed:23399697}.
CC   -!- CATALYTIC ACTIVITY: S-ubiquitinyl-[E2 ubiquitin-conjugating
CC       enzyme]-L-cysteine + [acceptor protein]-L-lysine = [E2 ubiquitin-
CC       conjugating enzyme]-L-cysteine + N(6)-ubiquitinyl-[acceptor
CC       protein]-L-lysine.
CC   -!- PATHWAY: Protein modification; protein ubiquitination.
CC   -!- PATHWAY: Protein modification; protein sumoylation.
CC   -!- SUBUNIT: Homooligomer. Interacts with MAP3K7/TAK1. Interacts with
CC       UBC9. Interacts with MAVS. {ECO:0000269|PubMed:18591963,
CC       ECO:0000269|PubMed:19407830, ECO:0000269|PubMed:23399697}.
CC   -!- INTERACTION:
CC       Q92624:APPBP2; NbExp=5; IntAct=EBI-744120, EBI-743771;
CC       Q9C026:TRIM9; NbExp=3; IntAct=EBI-744120, EBI-720828;
CC   -!- SUBCELLULAR LOCATION: Mitochondrion outer membrane; Multi-pass
CC       membrane protein. Peroxisome. Note=Transported in mitochondrion-
CC       derived vesicles from the mitochondrion to the peroxisome.
CC   -!- TISSUE SPECIFICITY: Widely expressed with highest levels in the
CC       heart, skeletal muscle, placenta, kidney and liver. Barely
CC       detectable in colon and thymus. {ECO:0000269|PubMed:18213395,
CC       ECO:0000269|PubMed:18591963}.
CC   -!- DOMAIN: The zinc finger domain is required for E3 ligase activity.
CC   -!- PTM: Ubiquitinated by PRKN during mitophagy, leading to its
CC       degradation and enhancement of mitophagy. Deubiquitinated by
CC       USP30. {ECO:0000269|PubMed:25621951}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; EU935008; ACH72645.1; -; mRNA.
DR   EMBL; AB097015; BAC77368.1; -; mRNA.
DR   EMBL; AK022937; BAB14317.1; -; mRNA.
DR   EMBL; AL833889; CAD38745.1; -; mRNA.
DR   EMBL; AL391357; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC010101; AAH10101.1; -; mRNA.
DR   EMBL; BC014010; AAH14010.1; -; mRNA.
DR   CCDS; CCDS208.1; -.
DR   RefSeq; NP_078820.2; NM_024544.2.
DR   UniGene; Hs.10101; -.
DR   ProteinModelPortal; Q969V5; -.
DR   SMR; Q969V5; -.
DR   BioGrid; 122734; 48.
DR   IntAct; Q969V5; 17.
DR   MINT; MINT-1464078; -.
DR   STRING; 9606.ENSP00000264198; -.
DR   iPTMnet; Q969V5; -.
DR   PhosphoSitePlus; Q969V5; -.
DR   BioMuta; MUL1; -.
DR   DMDM; 74760689; -.
DR   EPD; Q969V5; -.
DR   MaxQB; Q969V5; -.
DR   PaxDb; Q969V5; -.
DR   PeptideAtlas; Q969V5; -.
DR   PRIDE; Q969V5; -.
DR   DNASU; 79594; -.
DR   Ensembl; ENST00000264198; ENSP00000264198; ENSG00000090432.
DR   GeneID; 79594; -.
DR   KEGG; hsa:79594; -.
DR   UCSC; uc001bdi.5; human.
DR   CTD; 79594; -.
DR   DisGeNET; 79594; -.
DR   GeneCards; MUL1; -.
DR   HGNC; HGNC:25762; MUL1.
DR   HPA; HPA026827; -.
DR   MIM; 612037; gene.
DR   neXtProt; NX_Q969V5; -.
DR   OpenTargets; ENSG00000090432; -.
DR   PharmGKB; PA162396329; -.
DR   eggNOG; KOG1571; Eukaryota.
DR   eggNOG; ENOG410YF4M; LUCA.
DR   GeneTree; ENSGT00390000012141; -.
DR   HOGENOM; HOG000007562; -.
DR   HOVERGEN; HBG106376; -.
DR   InParanoid; Q969V5; -.
DR   KO; K15688; -.
DR   OMA; VCSCAEC; -.
DR   OrthoDB; EOG091G0OPO; -.
DR   PhylomeDB; Q969V5; -.
DR   TreeFam; TF325195; -.
DR   BRENDA; 6.3.2.19; 2681.
DR   Reactome; R-HSA-5689880; Ub-specific processing proteases.
DR   UniPathway; UPA00143; -.
DR   UniPathway; UPA00886; -.
DR   GenomeRNAi; 79594; -.
DR   PRO; PR:Q969V5; -.
DR   Proteomes; UP000005640; Chromosome 1.
DR   Bgee; ENSG00000090432; -.
DR   CleanEx; HS_MUL1; -.
DR   ExpressionAtlas; Q969V5; baseline and differential.
DR   Genevisible; Q969V5; HS.
DR   GO; GO:0030424; C:axon; IMP:ParkinsonsUK-UCL.
DR   GO; GO:0031307; C:integral component of mitochondrial outer membrane; IDA:UniProtKB.
DR   GO; GO:0016020; C:membrane; IDA:UniProtKB.
DR   GO; GO:0005739; C:mitochondrion; IDA:LIFEdb.
DR   GO; GO:0043025; C:neuronal cell body; IMP:ParkinsonsUK-UCL.
DR   GO; GO:0005777; C:peroxisome; IDA:UniProtKB.
DR   GO; GO:0042802; F:identical protein binding; IPI:UniProtKB.
DR   GO; GO:0004871; F:signal transducer activity; IMP:UniProtKB.
DR   GO; GO:0019789; F:SUMO transferase activity; IDA:UniProtKB.
DR   GO; GO:0031625; F:ubiquitin protein ligase binding; IPI:UniProtKB.
DR   GO; GO:0004842; F:ubiquitin-protein transferase activity; IDA:UniProtKB.
DR   GO; GO:0008270; F:zinc ion binding; IEA:InterPro.
DR   GO; GO:0006919; P:activation of cysteine-type endopeptidase activity involved in apoptotic process; IDA:UniProtKB.
DR   GO; GO:0007257; P:activation of JUN kinase activity; IDA:UniProtKB.
DR   GO; GO:0006915; P:apoptotic process; IEA:UniProtKB-KW.
DR   GO; GO:0071360; P:cellular response to exogenous dsRNA; IDA:UniProtKB.
DR   GO; GO:0000266; P:mitochondrial fission; IMP:UniProtKB.
DR   GO; GO:0051646; P:mitochondrion localization; IMP:UniProtKB.
DR   GO; GO:0030308; P:negative regulation of cell growth; IDA:UniProtKB.
DR   GO; GO:0071650; P:negative regulation of chemokine (C-C motif) ligand 5 production; IMP:UniProtKB.
DR   GO; GO:0050689; P:negative regulation of defense response to virus by host; IMP:UniProtKB.
DR   GO; GO:0045824; P:negative regulation of innate immune response; IMP:UniProtKB.
DR   GO; GO:0010637; P:negative regulation of mitochondrial fusion; IDA:UniProtKB.
DR   GO; GO:0051898; P:negative regulation of protein kinase B signaling; IDA:UniProtKB.
DR   GO; GO:0060339; P:negative regulation of type I interferon-mediated signaling pathway; IMP:UniProtKB.
DR   GO; GO:1903861; P:positive regulation of dendrite extension; IEA:Ensembl.
DR   GO; GO:0043123; P:positive regulation of I-kappaB kinase/NF-kappaB signaling; IMP:UniProtKB.
DR   GO; GO:0090141; P:positive regulation of mitochondrial fission; IDA:UniProtKB.
DR   GO; GO:1904925; P:positive regulation of mitophagy in response to mitochondrial depolarization; IEA:Ensembl.
DR   GO; GO:0033235; P:positive regulation of protein sumoylation; IDA:UniProtKB.
DR   GO; GO:0031648; P:protein destabilization; IMP:ParkinsonsUK-UCL.
DR   GO; GO:0050821; P:protein stabilization; IMP:UniProtKB.
DR   GO; GO:0016567; P:protein ubiquitination; IDA:UniProtKB.
DR   GO; GO:0051881; P:regulation of mitochondrial membrane potential; IEA:Ensembl.
DR   GO; GO:1901028; P:regulation of mitochondrial outer membrane permeabilization involved in apoptotic signaling pathway; IDA:UniProtKB.
DR   GO; GO:0010821; P:regulation of mitochondrion organization; IMP:ParkinsonsUK-UCL.
DR   CDD; cd00162; RING; 1.
DR   InterPro; IPR022170; GIDE.
DR   InterPro; IPR001841; Znf_RING.
DR   Pfam; PF12483; GIDE; 1.
DR   PROSITE; PS50089; ZF_RING_2; 1.
PE   1: Evidence at protein level;
KW   Apoptosis; Complete proteome; Isopeptide bond; Membrane;
KW   Metal-binding; Mitochondrion; Mitochondrion outer membrane;
KW   Peroxisome; Reference proteome; Transferase; Transmembrane;
KW   Transmembrane helix; Ubl conjugation; Ubl conjugation pathway; Zinc;
KW   Zinc-finger.
FT   CHAIN         1    352       Mitochondrial ubiquitin ligase activator
FT                                of NFKB 1.
FT                                /FTId=PRO_0000277660.
FT   TOPO_DOM      1      8       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM      9     29       Helical. {ECO:0000255}.
FT   TOPO_DOM     30    238       Mitochondrial intermembrane.
FT                                {ECO:0000255}.
FT   TRANSMEM    239    259       Helical. {ECO:0000255}.
FT   TOPO_DOM    260    352       Cytoplasmic. {ECO:0000255}.
FT   ZN_FING     302    340       RING-type. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00175}.
FT   CROSSLNK     52     52       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in ubiquitin).
FT                                {ECO:0000269|PubMed:25621951}.
FT   CROSSLNK    273    273       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in ubiquitin).
FT                                {ECO:0000269|PubMed:25621951}.
FT   CROSSLNK    299    299       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in ubiquitin).
FT                                {ECO:0000269|PubMed:25621951}.
FT   MUTAGEN     260    260       R->A: Protein is targeted to the ER; when
FT                                associated with A-261.
FT                                {ECO:0000269|PubMed:18213395}.
FT   MUTAGEN     261    261       K->A: Protein is targeted to the ER; when
FT                                associated with A-260.
FT                                {ECO:0000269|PubMed:18213395}.
FT   MUTAGEN     319    319       H->A: Abolishes ligase activity. No
FT                                effect on mitochondrial localization.
FT                                {ECO:0000269|PubMed:18591963}.
FT   MUTAGEN     339    339       C->A: Abolishes ligase activity.
FT                                {ECO:0000269|PubMed:18213395}.
FT   CONFLICT    240    240       W -> C (in Ref. 3; BAB14317).
FT                                {ECO:0000305}.
FT   CONFLICT    349    349       L -> P (in Ref. 1; ACH72645 and 2;
FT                                BAC77368). {ECO:0000305}.
SQ   SEQUENCE   352 AA;  39800 MW;  6EF2B8BBFCE1801F CRC64;
     MESGGRPSLC QFILLGTTSV VTAALYSVYR QKARVSQELK GAKKVHLGED LKSILSEAPG
     KCVPYAVIEG AVRSVKETLN SQFVENCKGV IQRLTLQEHK MVWNRTTHLW NDCSKIIHQR
     TNTVPFDLVP HEDGVDVAVR VLKPLDSVDL GLETVYEKFH PSIQSFTDVI GHYISGERPK
     GIQETEEMLK VGATLTGVGE LVLDNNSVRL QPPKQGMQYY LSSQDFDSLL QRQESSVRLW
     KVLALVFGFA TCATLFFILR KQYLQRQERL RLKQMQEEFQ EHEAQLLSRA KPEDRESLKS
     ACVVCLSSFK SCVFLECGHV CSCTECYRAL PEPKKCPICR QAITRVIPLY NS
//
